Continuing Education Activity

Oligomenorrhea is defined as irregular and inconsistent menstrual blood flow in a woman. Some change in menstrual flow is normal at menarche, postpartum, or in the perimenopausal period. This activity outlines the evaluation and management of oligomenorrhea and highlights the role of the interprofessional team in improving care for patients with this condition.

Objectives:

• Outline the etiology of oligomenorrhea.
• Describe the necessary steps in the evaluation of oligomenorrhea.
• Outline the management options available for oligomenorrhea.
• Summarize interprofessional team strategies for improving care coordination and communication to advance oligomenorrhea and improve outcomes.

Introduction

Oligomenorrhea is defined as irregular and inconsistent menstrual blood flow in a woman. Some change in menstrual flow is normal at menarche, postpartum, or in the perimenopausal period. But if a woman reports the length of menstrual cycle greater than 35 days or four to nine menstrual cycles in a year, then it is termed as oligomenorrhea. 

Menstrual flow should be normal before the development of oligomenorrhea.[1]

Etiology

Oligomenorrhea is often a sign of underlying disease. Following may be the causes of oligomenorrhea. 

• Polycystic ovarian disease[2]
• Androgen secreting tumor of the ovary[3]
• Androgen secreting tumor of the adrenal gland[4]
• Cushing syndrome
• Hyperthyroidism
• Prolactinomas
• Hypothalamic amenorrhea[5] 
• Pelvic inflammatory disease
• Asherman syndrome
• Uncontrolled diabetes mellitus
• Type-1 diabetes mellitus[6]
• Congenital adrenal hyperplasia[7]
• Non-classic congenital adrenal hyperplasia. 
• A side effect of oral contraceptive pills[8]
• Antipsychotics
• Antiepileptics
• Anatomic problems
• Primary ovarian insufficiency[9] 
• Exercising women with polycystic ovarian disease[10]

Epidemiology

The prevalence of oligomenorrhea is 13.5 percent in the general population.  A polycystic ovarian disease accounts for 4 to 10 percent of oligomenorrhea in women of reproductive age (from puberty to menopause). 11 to 44 percent of dancers and 6 to 60 percent of athletes report oligomenorrhea at some point in their life span.

History and Physical

History of oligomenorrhea includes a detailed history of menstruation, including duration of the menstrual cycle, the days of normal flow of menses in it, the number of pads used per day, the interval between two cycles, and the regularity of previous cycles. This information will give an idea about the amount of bleeding, the number of cycles in a year, and the regularity of menstrual cycles that will help to diagnose oligomenorrhea. Any irregularity of bleeding between menstrual cycles, hot flashes, and night sweats must be ruled out. The previous pattern of bleeding before the development of oligomenorrhea is important to know the baseline pattern of bleeding in the patient and the severity of change in that pattern.

Age of menarche, any sexual unprotected intercourse, abdomen pain, discharge, weight loss, are all necessary to determine the underlying cause. Any recent change in voice tone, hair growth, acne, blur vision, headaches, decreased libido, and production of milky discharge from nipples must be evaluated. Changes in bowel habits and skin also require evaluation.   

Birth history is essential in this regard. It may indicate infertility or any history of dilatation and curettage.  

In drug history, it is crucial to evaluate the use of birth control pills, antipsychotics, antiepileptics, and steroids.   

Family history may show Turner syndrome or polycystic ovarian disease in first degree relatives.[11]

PHYSICAL EXAMINATION  

Physical examination includes the following;  

• External examination.  
• Rectovaginal examination.   
• Vaginal speculum examination.  
• Abdomen examination.  

The external examination includes looking for any abnormal secondary sexual characteristics example, hair distribution, or clitoromegaly.  

The rectovaginal examination includes inserting a gloved finger lubricated with anesthetic gel to examine the walls of the vagina and to feel for any anatomic obstruction or abnormalities, tenderness in the abdomen, mass in adnexa or abdomen.

Vaginal speculum examination includes looking into the vagina and cervix with the use of a speculum. Look for any abnormal discharge, signs of inflammation, and growths.  

Abdomen examination includes inspection of the abdomen for ascites. Palpate the abdomen for masses and tenderness. Palpate the groin for inguinal lymphadenopathy. 

Evaluation

Labs to evaluate the cause of oligomenorrhea includes the following:  

Blood Tests

• FSH Levels; if increased, they show primary ovarian insufficiency.[12]  
• TSH levels; if decreased, then it shows hyperthyroidism.[13]  
• Prolactin levels; if increased, then prolactinoma may be the cause.[14]
• LH levels; the ratio of FSH\LH is useful in diagnosing polycystic ovarian disease.  
• Free testosterone levels; increased in congenital adrenal hyperplasia and polycystic ovarian disease.[15]
• 17 –OH levels; these are useful to diagnose congenital adrenal hyperplasia as a cause of oligomenorrhea.  
• Overnight dexamethasone suppression test; is done to diagnose Cushing syndrome as a cause of oligomenorrhea, especially if the patient presents with signs of this condition.
• HbA1C[6]

Investigations

• Ultrasound of abdomen and pelvis; it may indicate polycystic ovaries, signs of pelvic inflammation, and ascites.   
• CT scan is useful with suspicion of adnexal or adrenal masses.  
• MRI pituitary helps to confirm prolactinoma if prolactin levels increase.  
• Endocervical swabs are taken if there are signs of pelvic inflammatory disease.

Treatment / Management

Treatment of oligomenorrhea mainly depends on the underlying cause;  

Lifestyle Changes

Oligomenorrhea, when caused by low basal metabolic index and stress levels, can be dealt with behavior modification, diet, psychotherapy, and stress reduction techniques. Anovulation, when caused by obesity, can be managed with weight reduction.  

Hormonal Therapy

Birth control pills are often used to restore the regularity of the menstrual cycle, especially in Polycystic ovarian disease. They are safe to use, especially when the patient does not desire pregnancy.

Treating The Underlying Medical Conditions

If hyperthyroidism is the cause, then it is treated with antithyroid drugs, radioactive iodine or thyroidectomy. If the etiology is Cushing syndrome, then it is treated with medication that blocks excess cortisol overproduction example, ketoconazole, mitotane, and metyrapone. Prolactinomas, if small, can be treated with dopamine agonists example, bromocriptine, and cabergoline.  

Surgical Management

• Surgery may be necessary in the case of adnexal and adrenal tumors.
• Thyroidectomy may be necessary for hyperthyroidism.
• If prolactinoma is large enough to produce compressive symptoms, it may require surgical removal.

Differential Diagnosis

Menarche

Menarche is the first menstrual cycle in females. Its average age in the USA is 12.5 years. Girls may undergo initial anovulatory cycles that may cause light or irregular mensural flow that becomes regular overtime, which can be confused with oligomenorrhea, where initially women have established regular flow, and it gets lighter later on. 

Perimenopause

The irregular bleeding of perimenopause may be confused with oligomenorrhea, but mostly it is associated with accompanying sign and symptoms like hot flashes, vaginal dryness, night sweats, weight gain, mood changes and vaginal pain with intercourse whereas oligomenorrhea due to another medical condition will not be associated with such sign and symptoms.  

Irregular Bleeding 

Irregular bleeding may be confused with oligomenorrhea. Irregular bleeding is bleeding between cycles. It may indicate an endometrial polyp in premenopausal women or endometrial cancer in postmenopausal women. 

Pregnancy

It is crucial to make sure that cause of a delayed menstrual cycle is not a pregnancy. A pregnancy test is used for this purpose. A pregnancy test checks the urine or blood for a hormone called human chorionic gonadotropin (HCG). 

Pertinent Studies and Ongoing Trials

A small herbal medicine randomized controlled trial for oligomenorrhea and polycystic ovarian disease suggested that the individualized and standardized herbal medicine both have similar profiles in terms of safety and clinical effects in helping menstrual regularity.[16]

Prognosis

Oligomenorrhea itself is not a serious problem, but its underlying cause must be evaluated to avoid infertility. Moreover, if left untreated, it can increase the risk of endometrial hyperplasia and endometrial cancer. 

Complications

• Infertility: Untreated oligomenorrhea can lead to infertility in polycystic ovarian disease and primary ovarian insufficiency due to anovulation, impaired endometrium required for implantation in Asherman syndrome, fibrosis that occur as a result of pelvic inflammatory disease and metabolic derangement that occur in uncontrolled diabetes that makes pregnancy difficult. 
• Endometrial Hyperplasia: Oligomenorrhea that goes untreated for years can lead to endometrium proliferation and thus resulting in endometrial hyperplasia. 
• Endometrial Cancer: Endometrial hyperplasia is a precursor for endometrial cancer. Oral contraceptive pills that contain estrogen and progesterone are protective against endometrial cancer. 
• Osteoporosis: The main source of estrogen in the body is developing ovarian follicle that is lost due to anovulation in oligomenorrhea. This decrease in estrogen leads to osteoporosis. 
• Cardiovascular Problems: Estrogen is cardioprotective. Lack of estrogen due to anovulation leads to increase risk of myocardial ischemia. 
• Neuropsychiatric Complications: Anxiety, hallucination, delusion are psychiatric problems. Neurologic symptoms are involuntary movements in face and lips, anorexia, and asthenia.

Deterrence and Patient Education

Patients must note the date of their menstrual cycle every month and observe for any irregularity in the cycle or changes in the amount of bleeding during the cycles. Any sudden change must be noted. Patients must understand the normal physiology of the menstrual cycle and when to contact a doctor. A woman should contact a gynecologist if she goes more than 35 days without a period. All this education will help the patient to seek timely advice from the doctor. 

Regarding the use of birth control pills that are often used to maintain regularity of menstrual cycles in oligomenorrhea, patients must receive counsel regarding taking their medication regularly with fixed timings every day to increase its efficacy and to avoid withdrawal bleeding due to noncompliance of drugs. Patients must understand that they should not expect a pregnancy during the usage of drugs. If they desire a pregnancy, then alternative options for treatment must be explored.  

Enhancing Healthcare Team Outcomes

The multidisciplinary team approach that can improve outcomes in patients with oligomenorrhea includes a gynecologist to address the underlying cause of oligomenorrhea, a nutritionist to manage the weight of the obese patients, and a psychotherapist that will help women to cope with the mental pressure of delay or inability to conceive a child.  An endocrinologist is required to address the cause of diabetes mellitus and hyperthyroidism to improve the outcome of patients with oligomenorrhea.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Hennegan J, Brooks DJ, Schwab KJ, Melendez-Torres GJ. Measurement in the study of menstrual health and hygiene: A systematic review and audit. PLoS One. 2020;15(6):e0232935. [PMC free article: PMC7272008] [PubMed: 32497117]

2.

Gurbuz AS, Gode F. Dydrogesterone-primed ovarian stimulation is an effective alternative to gonadotropin-releasing hormone antagonist protocol for freeze-all cycles in polycystic ovary syndrome. J Obstet Gynaecol Res. 2020 Aug;46(8):1403-1411. [PubMed: 32500628]

3.

Kalashnikova MF, Likhodey NV, Tiulpakov AN, Fedorova EV, Bryunin DV, Bakhvalova AA, Glushakova MA, Smirnova SA, Fadeyev VV. [Virilizing ovarian tumor: the challenges of differential diagnosis]. Probl Endokrinol (Mosk). 2019 Dec 25;65(4):273-277. [PubMed: 32202730]

4.

Di Dalmazi G. Hyperandrogenism and Adrenocortical Tumors. Front Horm Res. 2019;53:92-99. [PubMed: 31499503]

5.

Pinelli G, Tagliabue A. Nutrition and fertility. Minerva Gastroenterol Dietol. 2007 Dec;53(4):375-82. [PubMed: 18043554]

6.

Deltsidou A, Lemonidou C, Zarikas V, Matziou V, Bartsocas CS. Oligomenorrhoea in adolescents with type 1 diabetes mellitus: relationship to glycaemic control. Eur J Obstet Gynecol Reprod Biol. 2010 Nov;153(1):62-6. [PubMed: 20702019]

7.

Engberg H, Möller A, Hagenfeldt K, Nordenskjöld A, Frisén L. Identity, Sexuality, and Parenthood in Women with Congenital Adrenal Hyperplasia. J Pediatr Adolesc Gynecol. 2020 Oct;33(5):470-476. [PubMed: 32473322]

8.

Banh C, Rautenberg T, Duijkers I, Borenzstein P, Monteil C, Levy-Gompel D, Klipping C, Scherrer B, Glasier A. The effects on ovarian activity of delaying versus immediately restarting combined oral contraception after missing three pills and taking ulipristal acetate 30 mg. Contraception. 2020 Sep;102(3):145-151. [PubMed: 32474062]

9.

Bensing S, Giordano R, Falorni A. Fertility and pregnancy in women with primary adrenal insufficiency. Endocrine. 2020 Nov;70(2):211-217. [PubMed: 32472424]

10.

Awdishu S, Williams NI, Laredo SE, De Souza MJ. Oligomenorrhoea in exercising women: a polycystic ovarian syndrome phenotype or distinct entity? Sports Med. 2009;39(12):1055-69. [PubMed: 19902985]

11.

Dabrowski E, Jensen R, Johnson EK, Habiby RL, Brickman WJ, Finlayson C. Turner Syndrome Systematic Review: Spontaneous Thelarche and Menarche Stratified by Karyotype. Horm Res Paediatr. 2019;92(3):143-149. [PubMed: 31918426]

12.

Siristatidis C, Pouliakis A, Sergentanis TN. Special characteristics, reproductive, and clinical profile of women with unexplained infertility versus other causes of infertility: a comparative study. J Assist Reprod Genet. 2020 Aug;37(8):1923-1930. [PMC free article: PMC7467999] [PubMed: 32504303]

13.

Colella M, Cuomo D, Giacco A, Mallardo M, De Felice M, Ambrosino C. Thyroid Hormones and Functional Ovarian Reserve: Systemic vs. Peripheral Dysfunctions. J Clin Med. 2020 Jun 01;9(6) [PMC free article: PMC7355968] [PubMed: 32492950]

14.

Kalsi AK, Halder A, Jain M, Chaturvedi PK, Sharma JB. Prevalence and reproductive manifestations of macroprolactinemia. Endocrine. 2019 Feb;63(2):332-340. [PubMed: 30269265]

15.

Kostopoulou E, Anagnostis P, Bosdou JK, Spiliotis BE, Goulis DG. Polycystic ovary Syndrome in Adolescents: Pitfalls in Diagnosis and Management. Curr Obes Rep. 2020 Sep;9(3):193-203. [PubMed: 32504286]

16.

Lai L, Flower A, Prescott P, Wing T, Moore M, Lewith G. Standardised versus individualised multiherb Chinese herbal medicine for oligomenorrhoea and amenorrhoea in polycystic ovary syndrome: a randomised feasibility and pilot study in the UK. BMJ Open. 2017 Feb 03;7(2):e011709. [PMC free article: PMC5293993] [PubMed: 28159846]

Disclosure: Yumna Riaz declares no relevant financial relationships with ineligible companies.

Disclosure: Utsav Parekh declares no relevant financial relationships with ineligible companies.